Comparing the current results to its competitors, Emergent Biosolutions Inc reported Revenue increase in the 2 quarter 2026 by 66.29 % year on year. The sales growth was above Emergent Biosolutions Inc 's competitors' average revenue growth of 6.29 %, achieved in the same quarter.
Emergent Biosolutions Inc , slower than the average decrease reported by the company's competitors of -31.5 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -31.5 %
Due to outstanding performance in Overall company, revenue grew by 66.29 % Emergent Biosolutions Inc improved its market share, to approximately 0.24 %.
November 6, 2024
In recent developments concerning infectious disease management, Emergent BioSolutions Inc. has announced its participation in a clinical trial evaluating the safety and efficacy of brincidofovir (brand name TEMBEXA) in treating the mpox virus across Africa. Sponsored by PANTHER and led by the Africa Centres for Disease Control and Prevention, this randomized, double-blind, placebo-controlled trial is a pivotal step in addressing mpox, particularly in a global landscape marked by significant public health challenges. This article explores the motivations behind the trial, the current context of mpox infections in Africa, and the economic landscape for Emergent BioSolutions amidst decreasing revenue and shif...
July 22, 2024
In a recent announcement, Emergent BioSolutions, a renowned biopharmaceutical company, shared exciting news regarding the extension of the shelf-life for their NARCAN Nasal Spray in Canada. The decision to expand the expiration date from three years to four years marks a significant achievement for the company, as it positions NARCAN Nasal Spray as the only intranasal naloxone spray in Canada with this extended shelf-life. This regulatory update, endorsed by Health Canada on February 2, 2024, has far-reaching implications for both Emergent BioSolutions and the healthcare landscape in Canada.Implications for the Company:This landmark regulatory decision will undoubtedly have a positive impact on Emergent BioS...
July 2, 2024
Strategic Reinforcement: Emergent BioSolutions Secures $250M in Contract Modifications to Enhance U.S. Medical Countermeasure StockpilesGAITHERSBURG, Md., July 02, 2024 Emergent BioSolutions Inc. (NYSE: EBS) has announced a significant milestone in the enhancement of the nation s medical countermeasure (MCM) stockpile. The company recently received contract modifications amounting to over $250 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS). These modifications underscore the ongoing commitment to fortifying the United States readiness against a spectrum of biological threats and public health emergencies, n...
April 30, 2024
Emergent BioSolutions Inc., a global life sciences company that specializes in emergencies of health and is known for its diverse portfolio of medicines and medical countermeasures, recently announced an amendment to its existing credit facility. The company, which has been a crucial player in the healthcare sector since its inception, entered into a Consent, Waiver, and Seventh Amendment to the facility.Operating under the ticker symbol EBS on the New York Stock Exchange, Emergent BioSolutions Inc., is headquartered in Gaithersburg, Maryland. The company is primarily invested in offering specialized products to healthcare providers and governments to address medical issues and emergencies. This credit facil...
March 25, 2024
Emergent BioSolutions Baltimore Bayview Manufacturing Facility Achieves No Action Indicated Status by FDAEmergent BioSolutions Inc. (EBS), a global specialty pharmaceutical company headquartered in Gaithersburg, Maryland, has recently announced that its Baltimore Bayview manufacturing facility has been granted No Action Indicated (NAI) status by the U.S. Food and Drug Administration (FDA). This classification signifies that the facility is now in compliance with the current good manufacturing practices (cGMP) set by the FDA.The Baltimore Bayview facility plays a crucial role in Emergent BioSolutions operations as it produces various vital products, including vaccines and pharmaceuticals, that are distribut...
January 11, 2024
Emergent BioSolutions Inc, a Maryland-based life sciences company, announced it has been awarded an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract, which has a maximum value of $235.8 million. The contract requires the company to supply its BioThrax Anthrax Vaccine Adsorbed to all branches of the U.S. military. BioThrax is the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA) for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis against anthrax disease in conjunction with recommended antibiotic treatment. It has a well-established safety profile and is administered to more than 10 million military personnel worldwide.The contract, which was le...
In a significant boost to Emergent BioSolutions Inc. (NYSE: EBS), the Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a contract option worth $75 million. This contract aims to procure doses of CYFENDUS, the newly licensed anthrax vaccine for the United States Department of Health and Human Services. The company expects to commence deliveries within this calendar year and complete them by the end of the first quarter of 2024. Additionally, Emergent BioSolutions Inc. has reported a revenue increase in the second quarter of 2023, although slightly lower than its competitors. BARDA Contract Option to Enable Acquistion of CYFENDUS: The recent award of a $7...
Xenetic Biosciences Inc is a biopharmaceutical company that focuses on developing personalized therapeutics with the potential to improve patient outcomes. The company employs a business model centered around leveraging its proprietary drug development platform to partner with pharmaceutical companies and advance novel drug candidates through preclinical and clinical stages.
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Arcus Biosciences Inc is a biotechnology company that focuses on developing immuno-oncology therapies. Their business model revolves around discovering and developing novel small molecule and antibody therapeutics to target various cancer indications. They aim to combine their extensive understanding of the immune system with innovative technology platforms to create effective treatments for patients with cancer.
Sources:
Emergent Biosolutions Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Emergent Biosolutions Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
